- Home
- IHS vs CLDX Comparison
IHS vs CLDX Comparison
Compare IHS & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IHS | CLDX |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | IHS | CLDX |
|---|---|---|
| Price | $8.42 | $28.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $8.00 | ★ $63.07 |
| AVG Volume (30 Days) | 703.7K | ★ 2.0M |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,743,000.00 |
| Revenue This Year | $13.39 | $19.74 |
| Revenue Next Year | N/A | $438.11 |
| P/E Ratio | $5.85 | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $5.71 | $22.10 |
| 52 Week High | $8.95 | $45.14 |
Technical Indicators
Market Signals| Indicator | IHS | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 25.66 |
| Support Level | $8.41 | $22.39 |
| Resistance Level | $8.46 | $28.27 |
| Average True Range (ATR) | 0.04 | 1.27 |
| MACD | -0.00 | -0.22 |
| Stochastic Oscillator | 78.57 | 1.42 |
Price Performance
Historical ComparisonAbout IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria and Sub-Saharan Africa. The majority of its revenue is derived from Nigeria.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.